Bioactive molecules derived from umbilical cord mesenchymal stem cells

Bai, Lipeng; Li, Danting; Li, Jie; Luo, Zhengzhong; Yu, Shumin; Cao, Suizhong; Shen, Liuhong; Zuo, Zhicai; Ma, Xiaoping

doi:10.1016/j.acthis.2016.09.006

Cited by 47 publications

(37 citation statements)

References 104 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Studies demonstrated that within 200 μm distance from the blood vessels is critical for the survival and retention of viable cells . Considering that VEGF plays a vital role in facilitating angiogenesis as well as stimulating osteogenesis by regulating related growth factors, osteoblasts, BMSCs, hUCMSCs or human adipose mesenchymal stem cells (hADMSCs) derived VEGF is much emphasized . An optimal concentration of VEGF is required for angiogenesis and osteogenesis coupling for intramembranous ossification on account that a higher or lower concentration of VEGF could result in compromised bone formation .…”

Section: Introductionmentioning

confidence: 99%

“…5 In contrast, MSCs from the Wharton's jelly of the neonatal umbilical cord, named human umbilical cord mesenchymal stem cells (hUCMSCs), possess a higher cell yield, rapid proliferation capacity, amounts of secreted cytokines related to cell migration, inflammation, immune regulation, angiogenesis (vascular endothelial growth factor [VEGF], insulin-like growth factor-1, transforming growth factor and platelet-derived growth factor [PDGF]), neurogenic and wound healing processes. [6][7][8] Above all, hUCMSCs do not express the major histocompatibility complex II (MHC II) and immunoregulatory factor B7 costimulatory molecules, which are responsible for the alloimmune response. 9 Therefore, it is believed that hUCMSCs own the characteristics of both seed cells and cytokines in the process of fabrication of tissue-engineered bone, which will be a promising choice to enhance the bioactivity of tissue-engineered bone graft.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

A novel method to improve the osteogenesis capacity of hUCMSCs with dual‐directional pre‐induction under screened co‐culture conditions

Rong

Zhou

et al. 2019

Cell Proliferation

View full text Add to dashboard Cite

Objectives Mesenchymal stem cells (MSCs) based therapy for bone regeneration has been regarded as a promising method in the clinic. However, hBMSCs with invasive harvesting process and undesirable proliferation rate hinder the extensive usage. HUCMSCs of easier access and excellent performances provide an alternative for the fabrication of tissue‐engineered bone construct. Evidence suggested the osteogenesis ability of hUCMSCs was weaker than that of hBMSCs. To address this issue, a co‐culture strategy of osteogenically and angiogenically induced hUCMSCs has been proposed since thorough vascularization facilitates the blood‐borne nutrition and oxygen to transport in the scaffold, synergistically expediting the process of ossification. Materials and methods Herein, we used osteogenic‐ and angiogenic‐differentiated hUCMSCs for co‐culture in screened culture medium to elevate the osteogenic capacity with in vitro studies and finally coupled with 3D TCP scaffold to repair rat's critical‐sized calvarial bone defect. By dual‐directional induction, hUCMSCs could differentiate into osteoblasts and endothelial cells, respectively. To optimize the co‐culture condition, gradient ratios of dual‐directional differentiated hUCMSCs co‐cultured under different medium were studied to determine the appropriate condition. Results It revealed that the osteogenic‐ and angiogenic‐induced hUCMSCs mixed with the ratio of 3:1 co‐cultured in the mixed medium of osteogenic induction medium to endothelial cell induction medium of 3:1 possessed more mineralization nodules. Similarly, ALP and osteogenesis/angiogenesis‐related genes expressions were relatively higher. Further evidence of bone defect repair with 3D printed TCP of 3:1 group exhibited better restoration outcomes. Conclusions Our work demonstrated a favourable and convenient approach of dual‐directional differentiated hUCMSCs co‐culture to improve the osteogenesis, establishing a novel way to fabricate tissue‐engineered bone graft with 3D TCP for large bone defect augmentation.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

A novel method to improve the osteogenesis capacity of hUCMSCs with dual‐directional pre‐induction under screened co‐culture conditions

Rong

Zhou

et al. 2019

Cell Proliferation

View full text Add to dashboard Cite

show abstract

“…Currently, it is known that umbilical cord mesenchymal stem cells can secrete a large number of bioactive molecules [40]. Many of them, such as TGF-b, EGF, FGF, VEGF and IGF, favour bone regeneration [41,42], the antioxidant effects of secretome also contribute to bone remodelling [34].…”

Section: Discussionmentioning

confidence: 99%

The therapeutic effect of secretome from human umbilical cord-derived mesenchymal stem cells in age-related osteoporosis

Liang

Liu

Peng

et al. 2019

Artificial Cells, Nanomedicine, and Biotechnology

View full text Add to dashboard Cite

Senile osteoporosis is closely related to the loss of function of stem cells. In this study, we tried to investigate the potential of secretome from human umbilical cord-derived mesenchymal stem cells (hUCMSCs) in recovering stem cell ability from senescence and then delaying bone loss. We first harvested bone marrow-derived mesenchymal stem cells (BMSCs) from young and old rats and then compared their cellular characteristics such as cell growth, anti-senescence and differentiation. The results showed that these abilities were negatively affected by animal aging. Subsequently, aged BMSCs were exposed to secretome from hUCMSCs, and we found that this loss of cell potential can be modified by secretome treatment. Thereafter, the secretome was loaded into silk fibroin-based hydrogels and used for an in vivo animal study. The results showed that compared to the old untreated group, the bone formation capacity of aged rats was improved by local treatment of secretome-loaded silk fibroin hydrogels. In conclusion, these findings demonstrated that secretome from hUCMSCs has the capacity to recover stem cell potential and delay local bone loss in age-related osteoporosis, which could potentially be applied in osteoporosis therapy in the future.

show abstract

“…These bioactive molecules can stimulate endogenous cell populations to undergo responses which may contribute to healing in a variety of tissues. Some of the most physiologically relevant biomolecules secreted by MSCs include hepatocyte growth factor (HGF), which has been reported to be involved in immunomodulation, cell migration, development, wound healing and antiapoptosis; transforming growth factor- (TGF-) β potentiated in immunomodulation, cell growth, proliferation and differentiation, and wound healing; vascular endothelial growth factor (VEGF), playing a large role in angiogenesis but also in immunomodulation and cell survival; and molecules such as tumor necrosis factor-stimulated gene- (TSG-) 6, prostaglandin E2 (PGE2), and galectins 1 and 9 which are all reported to play a large role in immunomodulation [ 19 , 20 ]. For a more detailed examination, see the thorough review by Bai et al [ 19 ] that describes the function of bioactive molecules secreted by umbilical cord-derived MSCs.…”

Section: The Composition Of the Msc Secretomementioning

confidence: 99%

Bioprocessing of Mesenchymal Stem Cells and Their Derivatives: Toward Cell-Free Therapeutics

Phelps

Sanati‐Nezhad

Ungrin

et al. 2018

Stem Cells International

130

111

View full text Add to dashboard Cite

Mesenchymal stem cells (MSCs) have attracted tremendous research interest due to their ability to repair tissues and reduce inflammation when implanted into a damaged or diseased site. These therapeutic effects have been largely attributed to the collection of biomolecules they secrete (i.e., their secretome). Recent studies have provided evidence that similar effects may be produced by utilizing only the secretome fraction containing extracellular vesicles (EVs). EVs are cell-derived, membrane-bound vesicles that contain various biomolecules. Due to their small size and relative mobility, they provide a stable mechanism to deliver biomolecules (i.e., biological signals) throughout an organism. The use of the MSC secretome, or its components, has advantages over the implantation of the MSCs themselves: (i) signals can be bioengineered and scaled to specific dosages, and (ii) the nonliving nature of the secretome enables it to be efficiently stored and transported. However, since the composition and therapeutic benefit of the secretome can be influenced by cell source, culture conditions, isolation methods, and storage conditions, there is a need for standardization of bioprocessing parameters. This review focuses on key parameters within the MSC culture environment that affect the nature and functionality of the secretome. This information is pertinent to the development of bioprocesses aimed at scaling up the production of secretome-derived products for their use as therapeutics.

show abstract

Bioactive molecules derived from umbilical cord mesenchymal stem cells

Cited by 47 publications

References 104 publications

A novel method to improve the osteogenesis capacity of hUCMSCs with dual‐directional pre‐induction under screened co‐culture conditions

A novel method to improve the osteogenesis capacity of hUCMSCs with dual‐directional pre‐induction under screened co‐culture conditions

The therapeutic effect of secretome from human umbilical cord-derived mesenchymal stem cells in age-related osteoporosis

Bioprocessing of Mesenchymal Stem Cells and Their Derivatives: Toward Cell-Free Therapeutics

Contact Info

Product

Resources

About